Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment

• Main Authors: Yudai Fujiwara (Author), Hidekatsu Kuroda (Author), Tamami Abe (Author), Keisuke Kakisaka (Author), Ippeki Nakaya (Author), Asami Ito (Author), Takuya Watanabe (Author), Kenji Yusa (Author), Tomoaki Nagasawa (Author), Hiroki Sato (Author), Akiko Suzuki (Author), Kei Endo (Author), Yuichi Yoshida (Author), Takayoshi Oikawa (Author), Kei Sawara (Author), Akio Miyasaka (Author), Takayuki Matsumoto (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background and Objective Durvalumab plus tremelimumab (Durva/Treme) has recently been approved as a first-line or later-line treatment for patients with unresectable hepatocellular carcinoma (u-HCC) in Japan. We assessed the real-world outcomes of Durva/Treme for u-HCC, with a focus on trea...